TSXV:CLAS.H - Post by User
Post by
WORKINMONTANAon Apr 26, 2021 9:24pm
![](https://assets.stockhouse.com/kentico-cms/0340-00/images/Sprite.svg#id_Post_Views_Icon)
185 Views
Post# 33072122
Pfizer Enrolling for PAH Program
Pfizer Enrolling for PAH Program https://www.pfizerclinicaltrials.com/C4041001
The Pfizer Clinical Research Unit is conducting a clinical trial with healthy volunteers to assess a study drug to potentially treat pulmonary arterial hypertension. This study will evaluate the dosing and safety of the study drug when taken orally.
Pulmonary arterial hypertension (PAH) is a rare disease that causes the arteries of the lungs to stiffen, resulting in increased blood pressure. People with PAH may have difficulty breathing, chest pain, and other complications. While some treatments are available to manage symptoms, PAH is a chronic disease that currently has no cure.